The slides that support the webinar presentation ‘An industry perspective on common practise in forced degradation studies of biopharmaceuticals’, presented on 15 June 2021.
Environmental Monitoring in Drug Product
Viewing related articles
read more
Environmental Monitoring (EM): A harmonized risk-based approach to selecting monitoring points and defining monitoring plans
Nov 2020 | Annex 1, Deliverable, Environmental Monitoring in Drug Product, Fill Finish, POI - Fill Finish, Publication
The purpose of an EM risk assessment (RA) is to provide information to determine how to distribute monitoring to best verify that processes are operating under control. This step-by step guidance covers the EM RA process and provides recommendations on monitoring sites and methods based on the relative probability of contamination industry guidance addresses these needs and attempts to capture best practices in a useable ‘toolkit’ format. The guide incorporates good practices from biopharmaceutical manufacturers and adheres to current regulatory guidelines.